PATENT CLAIM ANALYSIS

Application Number: 16216714
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["435", "006140"]

Abstract:
Process for the identification of compounds for treating cancer. The invention relates to a method for identifying candidate compounds for use as therapeutic agents for the treatment of cancer, among those who are able to activate the MDA-5 protein or increase NOXA protein levels and to trigger autophagy. It is based on the fact that activation of dsRNA sensor MDA-5 is able to trigger the destruction of cancer cells by activation both autophagy and apoptosis, autonomously and selectively in tumor cells, without provoking the stabilization of the natural antagonist NOXA, MCL-1. The invention also relates to the use of double-stranded RNAs of the same or similar nature such as polyinosinic-polycytidylic acid (pIC), complexed with carriers such as polyethylenimine polycation (PEI), for the manufacture of medicines for the treatment of cancer.

Claim (Index 39):
The method of  claim 22 , wherein the complex is administered intravenously.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 98.0
- Lexical Diversity: 1.7561
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15753328', '14352983', '13784903', '12836626', '15176812']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5909366521370139
- 35 USC 102 Novelty (BERT): 0.5285037460143407
- Combined Prediction Score: 0.5846933615247465
- Mean Citation Score: 271.1865839999999
- Max Citation Score: 287.2212
- Similarity Product: 151.9742668353081

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test